류마티스 관절염 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• Current Rheumatoid Arthritis Therapies such as biological DMARDs showed promising results in treating rheumatoid arthritis patients, and market penetration is expected to be more in the future and is expected to drive market growth. Oral classes such as Macrophage inhibitors are also expected to contribute to the rheumatoid arthritis market growth due to patient convenience towards oral drugs.
• In 2023, in the US the total Rheumatoid Arthritis Market Size was approximately USD 19,000 million.
• The geriatric population is a major end-user of rheumatoid arthritis drug treatment. The increase in the number of geriatric people leads to a high rate of ailments, which is likely to propel the demand for various drugs in the market.
• Despite the wide array of available treatments for rheumatoid arthritis, quality of life remains unmet across key domains such as pain, physical function, mental function, and fatigue.
• Currently, Cyxon is exploring its Macrophage inhibitor drug, Rabeximod, as an oral formulation. If approved, this will be the first oral Macrophage inhibitor with a unique mechanism of action and will create a good opportunity for the company.
• Since the pathophysiology of rheumatoid arthritis overlaps with that of other inflammatory diseases, most rheumatoid arthritis drugs will undergo label expansions into additional indications, such as ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ulcerative colitis.
• Failure of many BTK inhibitors such as fenebrutinib, evobrutinib, acalabrutinib, and others will create fear for others companies exploring the BTK inhibitor.
• Rheumatoid Arthritis is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Rheumatoid Arthritis Treatment Market report provides current treatment practices, emerging drugs, rheumatoid arthritis cancer market share of individual therapies, and current and forecasted rheumatoid arthritis market size from 2022 to 2036, segmented by seven major markets. The report also covers current rheumatoid arthritis treatment market practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Rheumatoid Arthritis drugs market.

Rheumatoid Arthritis Treatment Market: Understanding and Algorithm

Rheumatoid arthritis is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. It is the result of an immune response in which the body's immune system attacks its own healthy cells and the specific causes of RA are still unknown. Rheumatoid arthritis is more common in women and about 75% of RA patients are women. The disease most often begins between the ages of 30 and 50.

Rheumatoid Arthritis Diagnosis

Typically, rheumatoid arthritis is diagnosed by a combination of the patient's symptoms, results of the doctor's examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of disease-specific autoantibodies.

Rheumatoid Arthritis Treatment

Conventional DMARDs are a group of drugs (i.e., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that have been shown to affect the underlying cause of rheumatoid arthritis by damping down over-activity of the immune system, which helps to ease pain, swelling, and stiffness, and prevent changes occurring within the joint. Among csDMARDS, methotrexate (MTX) is considered a part of the first treatment strategy. MTX remains the anchor drug in rheumatoid arthritis; along with usage as monotherapy, it is also the basis for combination therapies, either with GC or with other csDMARDs, bDMARDs, or tsDMARDs. Patients refractory to csDMARDS or with severe symptoms are usually treated with a wide variety of biologics DMARDs classes like anti-TNF, T-cell inhibitors, B-cell Inhibitor, Interleukin Inhibitors and targeted synthetic DMARDs like JAK Inhibitors.

Rheumatoid Arthritis Epidemiology

The Rheumatoid Arthritis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Prevalent cases of Rheumatoid Arthritis, Diagnosed Prevalent cases of Rheumatoid Arthritis, Gender-specific Prevalent cases of Rheumatoid Arthritis, Age-specific Prevalent cases of Rheumatoid Arthritis, Severity-specific Prevalent cases of Rheumatoid Arthritis, Patients on targeted therapies of Rheumatoid Arthritis, and Line-Wise Treated Cases of Rheumatoid Arthritis in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

• The total diagnosed prevalent cases of rheumatoid arthritis in the 7MM was assessed to be ~4.2 million in 2025, and are projected to increase during the forecast period (2026-2036).
• In the US, the total prevalent cases of rheumatoid arthritis were ~1.5 million in 2025.
• Among EU4 and the UK, Germany accounted for the maximum number of moderate to severe cases of rheumatoid arthritis, followed by the UK, in 2025.
• In the US, there were nearly 460,000 cases of patients on targeted therapies in 2025, and these cases are expected to rise during the forecast period.

Rheumatoid Arthritis Recent Developments

• In March 2026, T-cell engager company Kali Therapeutics Inc. licensed its lead product, CD19/BCMA/CD3 trispecific antibody KT-501, to Sanofi SA in a global deal that could be worth more than $1.2 billion. The San Mateo, Calif.-based biotech first emerged in 2024 and moved KT-501 into a phase Ia trial last week to treat adults with rheumatoid arthritis.
• In January 2026, Lynk Pharmaceuticals Co., Ltd., a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, announced positive topline results from its Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to severe active rheumatoid arthritis (RA). The study met its primary and key secondary efficacy endpoints, demonstrating statistically significant improvements versus placebo (P < 0.0001), with a favorable safety and tolerability profile.
• In January 2026, SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced the publication of data from the RESET-RA study in Nature Medicine. The pivotal, double-blind, randomized, sham-controlled study evaluated the safety and efficacy of the SetPoint System, an implantable vagus nerve-targeted neuroimmune modulation device for adults living with moderately-to-severely active rheumatoid arthritis (RA) who are not adequately managed by-or cannot tolerate-existing advanced RA therapies, such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs).
• In October 2025, Artiva Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation to AlloNK(R) (also known as AB-101) for the treatment of refractory rheumatoid arthritis (RA) in combination with rituximab and that the Company has prioritized refractory RA as the program's lead indication.
• In October 2025, Imaging technology company Adaptix had begun live imaging trials as part of a research program at the University of Exeter. Patients suspected of having rheumatoid arthritis will be the first in the Untied Kingdom to use Adaptix Ortho350 technology to help diagnose and track the progression of the disease in their hands.

Rheumatoid Arthritis Drugs Chapters

Drug chapter segment of the Rheumatoid arthritis therapeutics market report encloses the detailed analysis of Rheumatoid arthritis-marketed drugs and early-stages (Phase-Ib and Phase-II) Rheumatoid Arthritis pipeline drugs analysis. It also helps to understand the Rheumatoid arthritis clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, the latest Rheumatoid Arthritis news, and press releases.

Rheumatoid Arthritis Marketed Drugs

• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation

OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis.

• RINVOQ (upadacitinib): AbbVie

RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.

In December 2019, the European Commission (EC) granted approval to RINVOQ for the treatment of adult patients with moderate to severely active RA who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Whereas, in January 2020, the Japan Ministry of Health Welfare and Labor approved the use of RINVOQ for the treatment of adult patients with moderate to severely active rheumatoid arthritis.

In December 2021, AbbVie announced that the U.S. label for RINVOQ will now include additional information about the risks of malignancy and thrombosis.

Rheumatoid Arthritis Emerging Drugs

• R-2487: Rise Therapeutics

R-2487 is a targeted oral immunotherapy designed to induce T regulatory cells and restore immune balance in autoimmune diseases, including rheumatoid arthritis. Its unique mechanism of action activates specific immune pathways to reset regulatory deficiencies and reduce inflammatory cytokines that drive autoimmune pathology. It is currently evaluating in Phase I of clinical trials.

• TAS5315: Taiho Pharmaceutical

TAS5315 is a novel, highly selective inhibitor of BTK. Targeting BTK may be efficacious against inflammation and bone erosion through direct regulation of activation of effector cells such as B cells, macrophages, and osteoclasts in rheumatoid arthritis. The company is evaluating a Phase II trial to evaluate safety and efficacy of TAS5315 in combination with methotrexate in participants with rheumatoid arthritis with inadequate response to methotrexate in Japan.

AZD1163 and AZD6912: AstraZeneca

AZD1163 is a first-in-class bispecific antibody that simultaneously targets and inhibits peptidyl arginine deiminases (PADs) 2 and 4. These enzymes are responsible for citrullinating proteins, leading to the formation of autoantigens that drive the autoimmune response in rheumatoid arthritis. By blocking PAD2 and PAD4 activity, AZD1163 aims to prevent the generation of these autoantigen.

AZD6912 is a small interfering RNA (siRNA) designed to inhibit human Complement Factor B (CFB), a key component of the alternative complement pathway. By suppressing CFB expression in the liver, AZD6912 aims to reduce systemic complement activation, which plays a significant role in inflammation and tissue damage in rheumatoid arthritis. AZD1163 (NCT06103877) is currently in Phase II clinical trials for rheumatoid arthritis. AZD6912 (NCT06115967) is in Phase I clinical trials for rheumatoid arthritis.

Rheumatoid Arthritis Drugs Market Insights

JAK inhibitors

The primary treatment choices for rheumatoid arthritis largely revolve around JAK inhibitors such as RINVOQ, which has seen significant success in the market. Other JAK inhibitors like OLUMIANT and TOFACITINIB are also available for this condition. However, there are concerns regarding the safety and effectiveness of JAK inhibitors, leading to black box warnings. In 2021, AbbVie revealed that the US labeling for RINVOQ would now incorporate further details about the potential risks of cancer and blood clotting issues.

Macrophage inhibitors

Macrophage inhibitors have been investigated in rheumatoid arthritis research as potential therapeutic agents. Rabeximod selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis. Clinical trials investigating rabeximod in rheumatoid arthritis have shown promising results in terms of modestly slowing the onset of disease and reducing disease severity in some patients. However, further research is needed to confirm its efficacy and safety in larger populations of rheumatoid arthritis patients.

Rheumatoid Arthritis Market Outlook

Currently, there is no cure for rheumatoid arthritis and no effective treatment to halt or reverse the progression of the disease. Treatment of patients with RA aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA.

HUMIRA was one of the top-selling drugs in the world and the strength of AbbVie. It was the first human monoclonal antibody to be approved for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active RA who have had an insufficient response to one or more traditional DMARDs. However, its patent has recently expired so various companies has developed HUMIRA's biosimilar.

Over the past few years, improvements in the field of rheumatoid arthritis have been observed however there is a necessity to have a profound understanding of the disease, and its unmet needs. Reflecting on these issues, the significance of dedicating resources to R&D is also imperative. To achieve great success in rheumatoid arthritis pricing policies must be considered because this further will help in the launch of a product that is truly attractive and appropriate to the market it is being launched into. All these factors help in building a strong product-market fit. At present, several companies have indulged themselves to initiate clinical trials that investigate new treatment options or study how to use existing treatment options better. The current developmental pipeline for rheumatoid arthritis is very robust. The dynamics of the rheumatoid arthritis market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world

Although the pipeline holds multiple promising therapies in various stages of development, most of which are vaccines. Therapies like Rabeximod (Cyxon), Imvotamab (IGM Biosciences), and others are the drugs and Monoclonal antibodies currently in Phase II and Ib trials focusing on Macrophage inhibition and CD cells depletion, and more may follow in the future. The current pipeline does not hold great potential as most of the products are currently in initial and mid stage trials and most of the drugs failed in their last stage trials as the studies did not meet primary and secondary efficacy endpoints in rheumatoid arthritis treatment. However, Rabeximod by Cyxone is a new drug candidate and unique among marketed drugs as well as drugs in development as it selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis.

Key Findings

• The total Rheumatoid Arthritis Market Size in the 7MM was estimated to be around USD 29,000 million in 2023, which is expected to grow during the forecast period (2026-2036).
• Rabeximod may emerge as an effective treatment option in Rheumatoid Arthritis Drugs Market as it directly addresses a clinical gap in rheumatoid arthritis treatment addressing beneficial tolerability, unique mechanism of action, and availability in both early and late stage of the disease.
• Entry of biosimilars are already started across the United States and EU (i.e., remicade biosimilars) and due to this sales value has started declining already and the impact will be more pronounced when biosimilars/ generics of some blockbuster drugs like HUMIRA (i.e., 2023 in the US), xeljanz (i.e., 2025 in US) will going to hit in to the market and this will impact the growth of RA market significantly.

Rheumatoid Arthritis Drugs Uptake

This section focuses on the uptake rate of potential Rheumatoid Arthritis drugs analysis expected to be launched in the market during 2026-2036. The Rheumatoid Arthritis treatment market landscape has experienced a transformation with the uptake of novel drugs. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of Rheumatologists, professors of rheumatology, and director of the University Hospital at Montpellier. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Rheumatoid Arthritis Pipeline Development Activities

The Rheumatoid Arthritis therapeutics market report provides insights into therapeutic candidates in Phase I and II. It also analyzes key Rheumatoid Arthritis Companies involved in developing targeted therapeutics. Rheumatoid Arthritis Companies like Cyxone, IGM Biosciences actively engage in late-stage research and development efforts for rheumatoid arthritis. The pipeline of rheumatoid arthritis possesses many potential drugs and there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2026-2036).

Pipeline Development Activities

The Rheumatoid Arthritis therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for rheumatoid arthritis emerging therapy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the rheumatoid arthritis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Rheumatology specialists, Rheumatology professors, and others.

DelveInsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Helios Department for Rheumatology, and Rheumatology Groups, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns in rheumatoid arthritis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Rheumatoid Arthritis Therapeutics Market: Qualitative Analysis

We perform Qualitative and Rheumatoid Arthritis therapeutics market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving Rheumatoid Arthritis treatment market landscape.

Rheumatoid Arthritis Therapeutics Market Access and Reimbursement

The treatment and management of rheumatoid arthritis are expensive. The significant expense for rheumatoid arthritis treatment comes from the patient's pocket, with palliative care and management having a major share of the out-of-pocket expenditure. Expensive Rheumatoid Arthritis Drugs like HADLIMA, RINVOQ pose a burden for rheumatoid arthritis patients as not everyone can get access to the drug due to its high cost.

Rinvoq Complete program by AbbVie is committed to providing exceptional access and patient support. The program provides nurse ambassadors who provide 1:1 support to help patients start and stay on track with their prescribed treatment plan. The program also provides a resource with expertise on medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient's unique financial situation. With the Complete Savings Card, commercially insured patients are eligible to pay as little as USD 5 per month. Rinvoq has achieved 95% Medicare coverage. To be eligible for the Rinvoq Complete program, the patients must have:

• Commercial insurance
• A valid Rx for rinvoq
• Experienced a delay or denial in insurance determination

The program provides rinvoq at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. The HADLIMA FOR YOU Patient Support Program helps patients with additional support throughout treatment including education resources, injection support, Co-pay assistance, and treatment related information. Humira Complete, also provides similar kinds of benefits as the RINVOQ Complete program.

Rheumatoid Arthritis Treatment Market Report Scope

• The Rheumatoid Arthritis treatment market report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the Rheumatoid Arthritis epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of mid-stage and prominent therapies will impact the current Rheumatoid Arthritis treatment market landscape.
• A detailed review of the Rheumatoid Arthritis treatment market, historical and forecasted Rheumatoid Arthritis treatment market size, Rheumatoid Arthritis drugs market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Rheumatoid Arthritis treatment market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive rheumatoid arthritis.

Rheumatoid Arthritis Treatment Market Report Insights

• Patient-based Rheumatoid Arthritis Market Forecasting
• Therapeutic Approaches
• Rheumatoid Arthritis Pipeline Drugs Analysis
• Rheumatoid Arthritis Market Size
• Rheumatoid Arthritis Market Trends
• Existing and Future Rheumatoid Arthritis Drugs Market Opportunity

Rheumatoid Arthritis Treatment Market Report Key Strengths

• 11 Years Rheumatoid Arthritis Market Forecast
• The 7MM Coverage
• Rheumatoid Arthritis Epidemiology Segmentation
• Key Cross Competition
• Rheumatoid Arthritis Drugs Uptake
• Key Rheumatoid Arthritis Market Forecast Assumptions

Rheumatoid Arthritis Treatment Market Report Assessment

• Current Rheumatoid Arthritis Treatment Market Practices
• Rheumatoid Arthritis Unmet Needs
• Rheumatoid Arthritis Pipeline Drugs Profiles
• Rheumatoid Arthritis Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

FAQs:

• What was the Rheumatoid Arthritis treatment market size, the Rheumatoid Arthritis market size by therapies, Rheumatoid Arthritis drugs market share (%) distribution in 2022, and what would it look like by 2036? What are the contributing factors for this growth?
• What can be the future treatment paradigm for rheumatoid arthritis?
• What are the disease risks, burdens, and unmet needs of rheumatoid arthritis? What will be the growth opportunities across the 7MM concerning the patient population with rheumatoid arthritis?
• What are the current options for the treatment of rheumatoid arthritis? What are the current guidelines for treating rheumatoid arthritis in the 7MM?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?
• What is the patient share in Rheumatoid Arthritis?

Reasons to Buy:

• The Rheumatoid Arthritis therapeutics market report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving rheumatoid arthritis.
• Insights on patient burden/disease Rheumatoid Arthritis prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Rheumatoid Arthritis drugs market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Rheumatoid Arthritis drugs market will help devise strategies to help get ahead of competitors.
• Detailed analysis ranking of class-wise potential current and emerging therapies under the analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Rheumatoid Arthritis drugs market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Flow Methodology

6 Rheumatoid Arthritis Market Overview at a Glance

• 6.1 Market Share (%) Distribution of Rheumatoid Arthritis by Class in 2025
• 6.2 Market Share (%) Distribution of Rheumatoid Arthritis by Class in 2036

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Stages of Rheumatoid Arthritis
• 7.3 Types of Rheumatoid Arthritis
  • 7.3.1 Seropositive Rheumatoid Arthritis
  • 7.3.2 Seronegative Rheumatoid Arthritis
• 7.4 Signs and Symptoms of Rheumatoid Arthritis
• 7.5 Risk Factors and Causes of Rheumatoid Arthritis
• 7.6 Complications of Rheumatoid Arthritis
• 7.7 Pathogenesis of Rheumatoid Arthritis
  • 7.7.1 Disease Initiation
  • 7.7.2 Triggers of Disease
  • 7.7.3 Citrullination
  • 7.7.4 Early and established Rheumatoid Arthritis
  • 7.7.5 Propagation of Disease
• 7.8 Diagnosis of Rheumatoid Arthritis
• 7.9 Screening of Rheumatoid Arthritis
• 7.10 Rationale and Impact for investigations following the diagnosis: NICE
  • 7.10.1 Evaluations of Disease Activity in Rheumatoid Arthritis
  • 7.10.2 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) classification criteria for Rheumatoid Arthritis

8 Treatment and Management of Rheumatoid Arthritis

• 8.1 Medications
  • 8.1.1 Conventional Disease-modifying antirheumatic drugs (DMARDs)
  • 8.1.2 Biological treatments
  • 8.1.3 Janus activated kinase (JAK) inhibitors
  • 8.1.4 Analgesics and Non-steroidal anti-inflammatory drugs (NSAIDs)
  • 8.1.5 Steroids
• 8.2. Supportive Treatment
  • 8.2.1 Physiotherapy
  • 8.2.2 Occupational therapy
  • 8.2.3 Podiatry
• 8.3 Surgery

9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology)

10 Treatment Guidelines for RA (National Institute for Health and Care Excellence)

11 Guidelines for Management of RA (American College of Rheumatology)

12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology)

13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR))

14 Treatment Algorithm

15 Epidemiology and Patient Population of 7MM

• 15.1 Key Findings
• 15.2 Assumptions and Rationale: 7MM
• 15.3 Total Prevalent Cases of Rheumatoid Arthritis in the 7MM
• 15.4 The United States
  • 15.4.1 Total Prevalent Cases of Rheumatoid Arthritis in the United States
  • 15.4.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
  • 15.4.3 Gender-specific Prevalent Cases of Rheumatoid Arthritis in the United States
  • 15.4.4 Age-specific Prevalent Cases of Rheumatoid Arthritis in the United States
  • 15.4.5 Severity-specific Prevalent Cases of Rheumatoid Arthritis in the United States
  • 15.4.6 Patients on targeted therapies of Rheumatoid Arthritis in the United States
  • 15.4.7 Line-Wise Treated Cases of Rheumatoid Arthritis in the United States
• 15.5 EU4 and the UK
  • 15.5.1 Total Prevalent Population of Rheumatoid Arthritis in EU4 and the UK
  • 15.5.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
  • 15.5.3 Gender-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
  • 15.5.4 Age-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
  • 15.5.5 Severity-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
  • 15.5.6 Patients on targeted therapies of Rheumatoid Arthritis in EU4 and the UK
  • 15.5.7 Line-Wise Treated Cases of Rheumatoid Arthritis in EU4 and the UK
• 15.6 Japan Epidemiology
  • 15.6.1 Total Prevalent Cases of Rheumatoid Arthritis in Japan
  • 15.6.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
  • 15.6.3 Gender-specific Prevalent Cases of Rheumatoid Arthritis in Japan
  • 15.6.4 Age-specific Prevalent Cases of Rheumatoid Arthritis in Japan
  • 15.6.5 Severity-specific Prevalent Cases of Rheumatoid Arthritis in Japan
  • 15.6.6 Patients on targeted therapies of Rheumatoid Arthritis in Japan
  • 15.6.7 Line-Wise Treated Cases of Rheumatoid Arthritis in Japan

16 Patient Journey

17 Key Endpoints in Rheumatoid Arthritis Clinical Trials

18 Marketed Drugs

• 18.1 Key Competitor
• 18.2 OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation
  • 18.2.1 Product Description
  • 18.2.2 Regulatory Milestones
  • 18.2.3 Other Developmental Activities
  • 18.2.4 Ongoing Current Clinical Pipeline Activity
  • 18.2.5 Pivotal Clinical Trial
  • 18.2.6 Safety and Efficacy
• 18.3 RINVOQ (upadacitinib): AbbVie
  • 18.3.1 Product Description
  • 18.3.2 Regulatory Milestones
  • 18.3.3 Other Developmental Activities
  • 18.3.4 Pivotal Clinical Trial
  • 18.3.5 Ongoing Current Clinical Pipeline Activity
• 18.4 ORENCIA (abatacept): Bristol Myers Squibb
  • 18.4.1 Product Description
  • 18.4.2 Regulatory Milestones
  • 18.4.3 Other developmental activities
  • 18.4.4 Pivotal Clinical Trials
  • 18.4.5 Safety and Efficacy
• 18.5 REMICADE (infliximab): Janssen Biotech
  • 18.5.1 Product Description
  • 18.5.2 Regulatory Milestones
  • 18.5.3 Other Developmental Activities
  • 18.5.4 Pivotal Clinical Trials
• 18.6 ENBREL (etanercept): Immunex/Amgen
  • 18.6.1 Product Description
  • 18.6.2 Regulatory Milestones
  • 18.6.3 Other developmental activities
  • 18.6.4 Pivotal Clinical Trials
• 18.7 RITUXAN/MABTHERA (rituximab): Genentech
  • 18.7.1 Product Description
  • 18.7.2 Regulatory Milestones
  • 18.7.3 Other Developmental Activities
  • 18.7.4 Pivotal Clinical Trials
• 18.8 CIMZIA (certolizumab-pegol): UCB
  • 18.8.1 Product Description
  • 18.8.2 Regulatory Milestones
  • 18.8.3 Other Developmental Activities
  • 18.8.4 Pivotal Clinical Trials

19 Emerging Drugs

• 19.1 Key Competitors
• 19.2 Rabeximod: Cyxon
  • 19.2.1 Product Description
  • 19.2.2 Other Developmental Activities
  • 19.2.3 Clinical Development
  • 19.2.4 Safety and Efficacy
• 19.2 Imvotamab: IGM Biosciences
  • 19.2.1 Product Description
  • 19.2.2 Other Developmental Activities
  • 19.2.3 Clinical Development
  • 19.2.4 Safety and Efficacy

20 Rheumatoid arthritis: 7MM Market Analysis

• 20.1 Key Findings
• 20.2 Market Outlook
• 20.3 Conjoint Analysis
• 20.4 Key Market Forecast Assumptions
• 20.5 Total Market Size of RA in the 7MM
• 20.6 United States Market Size
  • 20.6.1 Total Market size of RA in the United States
  • 20.6.2 Total Market size of RA by Class in the United States
  • 20.6.3 Total Market size of RA by Therapies in the United States
• 20.7 EU4 and UK Market Size
  • 20.7.1 Total Market size of RA in EU4 and the UK
  • 20.7.2 Total Market Size of RA by Class in EU4 and the UK
  • 20.7.3 Total Market size of Rheumatoid Arthritis by Therapies in EU4 and the UK
• 20.8 Japan Market Size
  • 20.8.1 Total Market size of RA in Japan
  • 20.8.2 Total Market Size of RA by Class in Japan
  • 20.8.3 Total Market size of Rheumatoid Arthritis by Therapies in Japan

21 Unmet Needs

22 SWOT Analysis

23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies

• 23.1 Access and Reimbursement RA therapies
• 23.2 Recent Access and Recommendations of RA Therapies
  • 23.2.1 US
  • 23.2.2 Europe
  • 23.2.3 Japan
• 23.3 Reimbursement Management

24 KOL Views

25 Appendix

• 25.1 Bibliography
• 25.2 Report Methodology

26 DelveInsight Capabilities

27 Disclaimer

28 About DelveInsight